These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 16842476

  • 21. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F, Shojaee Moradie F, Jones RH, Westergaard L, Haahr H, Umpleby AM, Russell-Jones DL.
    Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [Abstract] [Full Text] [Related]

  • 23. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ, Clauson P, Pedersen CB, Kølendorf K.
    J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
    [Abstract] [Full Text] [Related]

  • 24. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.
    Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
    [Abstract] [Full Text] [Related]

  • 25. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
    Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ.
    Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M, Abe N, Yokoyama H, Kuribayashi N, Tomonaga O, Matoba K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group.
    J Int Med Res; 2012 Aug; 40(2):787-97. PubMed ID: 22613444
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 33. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
    Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K.
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 39. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 40. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S, PREDICTIVE Turkey Study Group.
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.